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Abstract 
Background: In 2010, the World Health Organization issued a guideline that calls for a shift from presumptive to 
test-based treatment. However, test-based treatment is still unpopular in community pharmacies. This could be due 
to unwillingness of customers to spend extra finance on rapid diagnostic test (RDT). It could also result from lack of 
interest from community pharmacists since they may perceive no financial gain attached to this service. This study 
assessed the cost-benefit of test-based malaria treatment to community pharmacists.
Methods: The study was a community pharmacy-based cross sectional survey. Potential benefit of RDT was deter-
mined using customers’ willingness-to-pay (WTP) for service. Average WTP was estimated using contingent valuation. 
Binary logistic regression was used to assess correlates of WTP acceptance while multiple linear regression was used 
to model the relationship between the independent variables and WTP amount. Cost associated with provision of 
RDT was estimated from provider’s perspective. Probabilistic sensitivity analysis was used to capture parameter uncer-
tainty. Benefit-cost ratio (BCR) was calculated to determine study objective.
Results: A total of 135 out of 235 participants (57.4%) responded to the WTP question. Of this subset, 111 partici-
pants (82.2%) preferred RDT before malaria treatment. Average WTP [minimum–maximum] was US$1.23 [US$0.0–
US$5.03]. Educated participants had 1.8 times higher odds of WTP for RDT. Participants that understood RDT as 
described in the questionnaire had 18.3 times higher odds of WTP for RDT compared to participants that did not 
understand RDT as described in the questionnaire. Additionally, a unit increase in level of education (e.g. from primary 
to secondary school) led to US$0.298 increase in WTP amount for RDT. Also, a unit increase in malaria frequency (e.g. 
from ‘never’ to ‘rarely’) led to US$0.293 decrease in WTP amount for RDT. Average cost [minimum–maximum] of RDT 
test kit and pharmacist time spent in administering the test were US$0.15 [US$0.13–US$0.17] and US$0.41 [US$0.18–
US$0.52], respectively. BCR of test-based malaria treatment was 6.7 (95% CI 6.4–7.0).
Conclusion: Test-based malaria treatment is cost-beneficial for pharmacy practitioners. This finding could be used as 
an advocacy tool to increase community pharmacists’ interest and uptake of test-based malaria treatment.
Keywords: Malaria, Rapid diagnostic test, Cost-benefit analysis, Willingness-to-pay, Contingent valuation, Community 
pharmacy, Nigeria
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Background
Malaria is a major public health challenge and a lead-
ing cause of morbidity and mortality in Nigeria. The 
disease causes a substantial health burden. Nigeria and 
the Democratic Republic of Congo contribute more than 
35% of the global total of estimated malaria deaths [1]. 
Malaria accounts for about 60% of outpatient visits, 30% 
of hospitalization and it is believed to contribute up to 
11% of maternal mortality, 25% of infant mortality, and 
30% of under-5 mortality [2]. The disease is estimated to 
retard Nigeria’s gross domestic product (GDP) by 40% 
annually and costing approximately 480 billion naira 
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(approximately US$1.5 billion) in out-of-pocket treat-
ments, prevention costs, and loss of man hours [2].
Approaches in malaria diagnosis include clinical diag-
nosis, microscopic diagnosis, molecular diagnosis and 
serology [3], with clinical and presumptive diagnosis being 
the conventional diagnostic method [4]. However, clini-
cal diagnosis using fever as an indicator has been shown 
to be a sensitive indicator of clinical malaria in children 
<5  years, but not in older children and adults [5]. Other 
diagnostic approaches require trained staff, expensive and 
fragile equipment, and electricity supply among others. 
These requirements and inherent potential for human and 
technical errors have been shown to result in misdiagnosis 
and over-diagnosis of malaria [3, 4, 6–9]. This over-diag-
nosis of malaria exposes patients to needless anti-malarial 
therapy, waste of resources in resource-scarce setting, and 
may likely contribute to the development of drug resist-
ance [10, 11]. The problem of misdiagnosis and over treat-
ment of malaria led to the development of a more reliable, 
field-suitable and cost-effective diagnostic tool–rapid diag-
nostic test (RDT) [12, 13]. Rapid diagnostic test, based on 
the detection of Plasmodium antigens in a little drop of the 
patients’ blood, saves cost and time while giving an almost 
instant result. It generally has high level of sensitivity and 
specificity, although its accuracy varies between brands, 
location and epidemiological setting [14, 15]. The accuracy 
and reliability of RDT made it a staple in malaria control 
programmes and a first choice malaria diagnostic tool 
[16, 17]. RDTs testing for falciparum malaria were shown 
in a Cochrane review to be very specific (range of about 
92–100%) meaning that only 0–8% of patients who test 
positive would not actually have the disease [18]. Further-
more, they were shown to be very sensitive (range of about 
91–99%) meaning that only 1–9% of people with falcipa-
rum malaria would actually get a negative test result [18].
To effectively diagnose and treat malaria, World Health 
Organization in 2010 issued guideline that moved from 
select implementation of malaria testing to adoption of 
universal testing including children under 5  years [19]. 
Practically, this implies that in all suspected cases, the diag-
nosis of uncomplicated malaria should be confirmed using 
a parasitological test (either microscopy or RDT) prior to 
treatment [20, 21]. Arguments in favour of the shift to test-
based management of malaria were of the opinion that 
the factors which justified presumptive approach were no 
longer valid namely: high malaria transmission; availabil-
ity of affordable yet effective antimalarial drugs; and lack 
of appropriate diagnostic tools. They also argued that test-
based approach would lead to improvement in the manage-
ment of non-malaria febrile illness [18, 22–24]. Consistent 
with the WHO recommendation, Nigeria in 2011 updated 
the national malaria treatment guideline to reflect universal 
testing before treatment for suspected cases of malaria [25].
In most African countries, large proportions of the 
population utilize the private sector, particularly drug 
shops, as their first point of care for fever and malaria 
treatment [26, 27]. This is similar to the situation in Nige-
ria, in which nearly 60% of Nigerians seek treatment for 
malaria at drug shop outlets in the private health sec-
tor, composed of licensed community pharmacies (or 
referred to as pharmacies) and loosely regulated pro-
prietary and patent medicine vendors (PPMV) [15, 28, 
29]. This treatment-seeking behaviour is attributed to 
patients’ convenience, availability of familiar drugs, 
affordability, reduced waiting hour and proximity [30].
The expected responsibilities of community phar-
macists in the prevention and management of malaria 
is anchored on the pharmaceutical care principle of 
responsible provision of drug therapy in order to improve 
patients’ quality of life [31, 32]. With anti-malarial drugs 
being an ‘over-the-counter’ medication in Nigeria, com-
munity pharmacists have the responsibility of ensur-
ing that patients seeking anti-malarial drugs truly have 
malaria before recommending the appropriate anti-
malarial drugs in line with WHO call for routine diag-
nostic test in all suspected cases of malaria prior to 
treatment. Despite the call for a shift from presumptive 
to test-based treatment, uptake of RDT by formal and 
informal drug vendors remain low, as malaria treatment 
is still mostly based on presumptive approach [33, 34].
The non-provision of RDT service in Nigerian com-
munity pharmacies could be connected to the fact that 
patients with suspected cases of malaria may not be will-
ing to spend extra money for RDT in addition to anti-
malarial drugs. Community pharmacists may also be 
interested in making more sales for better financial gains 
rather than spending time to offer such RDT service. 
Thus, community pharmacists may need to be incentiv-
ized to offer RDT service. A previous Nigeria-based study 
assessed the willingness to pay (WTP) for RDT in health 
centres and households ex ante and ex post to malaria 
diagnosis [35]. However, review of literature showed that 
no study has assessed the financial benefit of test-based 
malaria treatment from the community pharmacist’s 
perspective. This study was, therefore, aimed at assess-
ing the willingness to pay (WTP) for malaria RDT among 
patients visiting community pharmacies for malaria 
treatment using a contingent valuation method and the 
cost-benefit of test-based malaria treatment to the com-
munity pharmacy practitioner.
Methods
Study design and study population
As shown in Fig.  1, the pharmacy-based cross sectional 
study was carried out in Enugu metropolis, in south 
eastern part of Nigeria, from November 2015 to March 
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2016. Enugu state, also known as the Coal City State, is 
located within latitude 6°.00′N and 7°.00′N and longi-
tude 7°.00′E and 7°.45′E, and has Ibos as its indigenous 
ethnic group [36]. Enugu has an estimated population of 
3,257,298 [37], and there were 98 community pharmacies 
registered with Pharmacist Council of Nigeria in the state 
as at January 2015. Enugu was purposively selected since 
different cadres of pharmacies operate in the city.
Community pharmacies selected for the study were 
those registered with Pharmacist Council of Nige-
ria (PCN) and those that have a full or part time 
pharmacist(s) working in the pharmacy. With a popula-
tion of 98 pharmacies and assuming a confidence level of 
95% with a confidence interval of ±12, a sample size of 
40 pharmacies was estimated to be adequate for the sur-
vey [38]. Stratified sampling technique was employed to 
Fig. 1 Map of Nigeria highlighting the local government areas (LGA) were the study was conducted in Enugu State. 1 = Enugu North LGA; 
2 = Enugu South LGA; 3 = Enugu West LGA
Page 4 of 10Ezennia et al. Malar J  (2017) 16:7 
select pharmacies for the study ensuring the inclusion of 
persons from high, middle and low socioeconomic class. 
Enugu metropolis was divided into ten strata namely: 
Trans-ekulu, Abakpa, New heaven, Coal camp, Inde-
pendence layout, Ogui, Achara layout, Uwani, GRA and 
Ogbete, from which four community pharmacies were 
randomly selected from each stratum. Patients not less 
than 18 years, who had the ability to read and write, those 
with suspected cases of malaria, and those that gave con-
sent were invited to participate in the study.
Benefit estimate: willingness‑to‑pay for RDT
Contingent valuation approach using the payment card 
technique was used to estimate the average maximum 
willingness-to-pay (WTP) among the survey partici-
pants. Self administered questionnaire was developed for 
the WTP assessment (Additional file  1). The question-
naire consisted of three sections. Section A contained 
socio-demographic information of the respondents. 
Section B consisted of attitude of respondents towards 
malaria. Section C assessed respondents willingness to 
pay (WTP) after a brief scenario description. RDT pref-
erence was assessed based on the response to the follow-
ing question: “Will you be willing to pay for RDT so as 
to be tested for malaria in the pharmacy before initiation 
of treatment”? The follow-up question was used to assess 
willingness to pay (WTP) of those that prefer RDT before 
treatment. The question reads as follows: “How much will 
you be willing to pay for the RDT from the scale below. 
Offered WTP values in the payment card ranged from 50 
Naira to more than 1000 Naira (equivalent to US$0.25–
US$5). The maximum amount they were willing to pay 
was considered as their perceived monetary benefit of 
the RDT. This is in accordance with welfare economic 
theory which states that the benefit to an individual of a 
service or intervention is defined as the individual’s maxi-
mum willingness to pay for the service or intervention.
The elicitation format employed in determining 
respondents’ WTP was the payment scale/card and 
open-ended question. The payment scale presented 
respondents with a range of values to choose from, in a 
vertical list from the lowest bid (top) to the highest bid 
(bottom) in increments. The open-ended question on 
the other hand was employed if the maximum WTP was 
greater than the highest bid in the scale and also to find 
out respondent’s reason for choosing their maximum 
WTP amount. Different payment scales with different 
ranges were randomly allocated across the study sam-
ple to avoid range bias. The questionnaire was face vali-
dated, to assess the presentation as well as the relevance 
of the questionnaire, and pilot tested to assess feasibility. 
Modifications were made to the questionnaire based on 
any identified problem(s) during the pilot study. The final 
questionnaire was distributed in the selected pharma-
cies in Enugu after obtaining oral informed consent from 
respondents.
Responses to the WTP question were grouped into two 
categories: those that prefer RDT before treatment and 
those that prefer presumptive treatment (RDT rejecters). 
The response to WTP question served as the dependent 
variables in a multivariate binary logistic regression. The 
independent variables were re-categorized into the fol-
lowing variables:
i. Socio-economic data: sex, age of respondents 
(4 dummy codes for 21–30  years, 31–40  years, 
41–50  years, and >50  years), number of children (4 
dummy codes for 2, 3, 4, and >4 children), level of 
education (4 dummy codes for primary, secondary, 
tertiary and post-tertiary education), average house-
hold income (5 dummy codes for US$50–US$251, 
US$251–US$502, US$502–US$1256, US$1256–
US$2512, >US$2512), whether respondent is 
employed (5 dummy codes for farming, civil servant, 
trader, self-employed, others).
ii. Malaria and RDT experience—Frequency of malaria 
in household (4 dummy codes for rarely, sometimes, 
often, always); importance of testing, and under-
standing of RDT.
Additionally, linear regression was used to model the 
relationship between the independent variables and the 
amount the respondents were willing-to-pay for RDT. 
Data was initially coded and transferred to Microsoft 
Excel (Microsoft Office 2010). Further re-categorization 
of data (i.e. creation of dummy variables) was done in 
Microsoft Excel before it was imported to SPSS (Version 
20). Logistic regression and linear regression were per-
formed employing the backward conditional method and 
the independent variables above serving as the predictor 
variable. A two-tailed significance value of 0.05 was used.
Cost estimate
Cost was estimated from the health provider’s per-
spective. The prevailing community pharmacists’ sala-
ries were used. The salaries of the three basic cadres of 
pharmacists that work in community pharmacies were 
obtained from the study sites. Since the three basic cad-
res of pharmacists earn differently, they were used to 
obtain the minimum, most likely and maximum values of 
staff cost. Using the average working hour, the cost of the 
15  min of pharmacists’ time was deduced to represent 
the time spent on administration of malaria RDT ser-
vice [35, 39, 40]. The minimum, average and maximum 
distributor’s price for malaria RDT kit was obtained for 
all the commonly available RDT kits in Enugu. Cost of 
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consumables such as alcohol for disinfection, lancets, and 
hand gloves were not included since they are covered in 
the unit cost of RDT kit (i.e. they were already contained 
in the RDT kit).
Benefit‑cost analysis
Cost benefit of test-based malaria treatment with RDT 
from the community pharmacists’ perspective was cal-
culated by dividing benefits over costs, referred to as a 
benefit-cost ratio (BCR). A ratio >1 demonstrated a posi-
tive return on investment. In this analysis the potential 
benefit was measured as WTP for RDT service. The costs 
included the pharmacist’s time for administering RDT 
and the cost of RDT kit.
Using the average estimates of parameters to calculate 
BCR will be misleading since the cost parameters varied 
widely in reality. Therefore, probabilistic sensitivity analy-
sis (PSA) approach was used to account for parameter 
uncertainty [41]. The PSA allowed exploration of the joint 
uncertainty in costs and benefit estimates. Triangular 
distributions of each parameter were used for PSA cal-
culation. A thousand Monte Carlo simulations were run 
and the mean [95% confidence interval] of BCR was pre-
sented. Specifically, a point estimate was drawn randomly 
from the distribution of each parameter used in estimat-
ing BCR. This was repeated for 1000 times (a thousand 
iterations) and then the average of the 1000 iterations with 
95% confidence interval calculated. Monte Carlo simula-
tion was conducted using Microsoft Excel 2010.
Results
Characteristics of respondents
A total of 235 respondents successfully answered the 
questionnaire, one half were male while the other half 
were female. Majority of the respondents who partici-
pated in the survey were aged 21–30  years, single and 
from Ibo tribe. Most of the respondents had a formal 
education, with more than half (53.7%) with tertiary edu-
cation. About half of the respondents (57.5%) reported 
earning a monthly income of US$50–US$502 (Table 1).
Average WTP value for RDT and its predictors
Table  2 shows the WTP value for malaria RDT kit. A 
total of 135 out of 235 participants (57.4%) responded 
to the WTP question. Of this subset, 111 participants 
(82.2%) stated that they prefer RDT before malaria treat-
ment while 24 (17.8%) stated that they prefer presump-
tive treatment. The reason given by majority of the 
respondents for rejecting RDT and choosing presumptive 
treatment was majorly due to financial considerations. 


































Post tertiary 56 (24.7)
Occupation
No job 49 (22.1)
Farming 10 (4.5)
Civil servant 48 (21.6)
Trader 16 (7.2)
Self employed 57 (25.7)
Others 42 (18.9)
Monthly income
<US$50 (N10,000) 33 (18.4)
US$50–US$251 (₦10,000–₦50,000) 67 (37.4)
US$251–US$502 (₦50,000–₦100,000) 36 (20.1)
US$251–US$502 (₦50,000–₦100,000) 29 (16.2)
US$1256–US$2512 (₦250,000–₦500,000) 9 (5.0)
>US$2512 (>₦500,000) 5 (2.8)
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In other words, patients who were not willing to pay for 
RDTs may still prefer to get tested before treatment if the 
testing were free. The stated average WTP [minimum–
maximum] by the respondents was US$1.23 (US$0.0–
US$5.03). Fifty percent of the respondents stated US$1.01 
as their WTP amount while the most frequently stated 
WTP amount was US$0.50. Figure  2 shows the willing-
ness to pay demand curve which depicts the relationship 
between the price of RDT and the percentage of patients 
willing to pay to get tested. The demand curve had a neg-
ative slope, moved downward from left to right, consist-
ent with the law of demand. This implied that as the price 
of RDT increased, the percentage of patients willing to 
pay decreased, all things being equal.
Logistic regression examining predictors of RDT 
acceptance showed that educated participants had 1.8 
times higher odds of WTP for RDT before initiation of 
malarial treatment (Table  2). Participants that under-
stood RDT from the description provided in the ques-
tionnaire had 18.3 times higher odds of preferring to 
undergo RDT before the initiation of malarial treatment 
compared to participants that did not understand RDT 
from the description provided in the questionnaire. The 
predictive capacity of the model was 18.1%. Additionally, 
multiple linear regression examining predictors of WTP 
amount for RDT showed that two variables (education and 
frequency of malaria infection) predicted WTP amount 
for RDT, F(2, 97) = 5.169, p = 0.007, R2 = 0.096 (Table 2). 
Each of the two variables added statistically significantly to 
the prediction, p < 0.05. Specifically, a unit increase in level 
of education (e.g. from primary to secondary school) led to 
US$0.298 increase in WTP amount for RDT. Also, a unit 
increase in malaria frequency (e.g. from ‘never’ to ‘rarely’) 
led to US$0.293 decrease in WTP amount for RDT.
RDT cost and cost‑benefit analysis
Three categories of community pharmacists (com-
munity pharmacy owners, superintendent community 
pharmacists and locum community pharmacists) were 
interviewed to obtain average (minimum–maximum) 
community pharmacist’s salary. Pharmacist’s time spent 
in administering RDT was prorated from the average 
community pharmacist’s salary. Fifteen minutes was 
assumed to be pharmacist’s time spent on administer-
ing RDT. This was based on observation of a trial RDT 
procedure in a community pharmacy as well as reports 
from literature [35, 39, 40]. Cost of RDT kit was obtained 
from major distributors of pharmaceuticals and medi-
cal products in Ogbete main market, Enugu. The average 
cost (minimum–maximum) of 15 min of pharmacist time 
spent in administering the test and RDT kit were US$0.41 
(US$0.18–US$0.52) and US$0.15 (US$0.13–US$0.17), 
Table 2 WTP amount for malaria rapid diagnostic test and its predictors (n = 135)







Dependent: RDT acceptance (=1), n = 111 and RDT rejection (=0), n = 24
B b(exp) Sig
Binary logistic regression
Education 0.608 1.836 0.123
Understanding of RDT 2.909 18.343 0.003
Constant −3.989 0.019 0.003
Nagelkerke R2 0.181
Dependent: Maximum WTP amount, n = 111
B Std. Error Sig
Multiple linear regression
Education 0.298 0.130 0.024
Malaria frequency −0.293 0.120 0.017
Constant 0.836 0.436 0.058
R2 0.096
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respectively. The BCR of the test-based malaria treatment 
was 6.7 (95% CI 6.4–7.0). Further details are shown in 
Table 3.
Discussion
This study assessed the willingness to pay (WTP) for 
malaria rapid diagnostic testing among patients visiting 
community pharmacies for anti-malarial drugs. The aim 
of the study was to evaluate the cost-benefit of offering 
test-based malaria treatment from the community phar-
macist’s perspective. The findings showed that aver-
age WTP [minimum–maximum] for RDT was US$1.23 
[US$0.0–US$5.03] and return on invested time was 
approximately 7 times for the community pharmacist. 
Educated patients and hose with good comprehension of 
RDT from the description provided in the questionnaire 
were more likely to accept testing with RDT before treat-
ment. Similarly, being educated was related with higher 
value placed on RDT while patients with higher fre-
quency of malaria infection placed lower value on RDT.
The results obtained in this study were similar to pre-
viously published studies. This study showed that the 
majority of the participants were willing to pay an aver-
age of US$1.23. This is comparable to the findings of 
Uzochukwu et  al. [35] which showed a mean ex-ante 
willingness to pay for RDT of US$1.18 in the urban area. 
I = Inelastic; E = Elastic 
Price (US$) 0.25 0.50 0.75 1.01 1.26 1.51 2.01 2.51 3.02 5.03
Proporon WTP (%) 97.1 87.8 56.1 50.4 28.1 26.1 20.9 17.3 7.2 6.5 
Elascity Coefficient (Ed) - 0.09 0.72 0.29 1.79 0.27 0.65 0.69 2.87 0.15
Descripon - I I I E I I I E I 
Fig. 2 Willingness-to-pay demand curve and price elasticity of demand
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Also, the finding that educated participants were more 
likely to prefer test-based malaria treatment is similar to 
a study in Uganda, which showed that a higher WTP was 
associated with respondents who had higher level of edu-
cation [42].
This study has practical inferences for maximizing the 
utilization of test-based malaria treatment in community 
pharmacies and proprietary and patent medicine ven-
dors (PPMV), particularly for malaria endemic regions. 
Among the participants that responded to the WTP 
question, a total of 82.2% of the respondents were will-
ing to pay for RDT services, indicating a high demand for 
the service. The most frequently stated willingness to pay 
amount is greater than the existing market price of RDT, 
reflecting that majority of the participants have value for 
RDT and are willing to utilize it if made available. Not-
withstanding, a number of factors may have influenced 
those that rejected RDT or those that did not answer 
the WTP question. This may include difficulty in placing 
value on an unfamiliar commodity and viewing of RDT 
as an extra cost in addition to the cost of medication, 
thus perceiving it as unaffordable [42]. This highlights an 
immense need for awareness and education of the masses 
as well as pharmacy practitioners on the importance 
and benefits of test-based malaria treatment in order to 
increase its utilization. Such intervention could lead to 
overall change in public perception of RDT [33]. It may 
also be important to explore offering RDT and malaria 
treatment as a single bundled commodity rather than two 
separate commodities [42]. Such strategy could improve 
uptake of RDT. Finally, it is important to explore the use 
of subsidies for RDT especially as financial constraint 
was a major reason for those that choose presumptive 
treatment rather that test-based treatment [35, 42].
Furthermore, findings from our study showed a BCR 
of 6.7. This implies that test-based malaria treatment 
will generate a return that amounts to approximately 7 
times the cost of investment. Thus, the positive return on 
investment could be used as an advocacy tool to increase 
the interest of community pharmacy practitioners on 
test-based malaria treatment. The pharmacists were 
interviewed to ascertain why they do not make RDTs 
available in their pharmacies. Although not originally 
part of the study objectives, interview of the pharma-
cists revealed that most of them perceive the results of 
RDT as inaccurate especially when the results are nega-
tive. Majority of the pharmacists interviewed believe that 
a patient presenting with signs and symptoms of malaria 
must test positive to RDT. Similarly, some of the pharma-
cists view RDT as an additional cost to the cost of malaria 
medication and as such, they believe that patients may 
not be willing-to-pay for RDT. Lastly, most pharma-
cists think test-based treatment will reduce their sales 
especially as they deem their practice a profit-oriented 
venture.
There is a caveat to promoting RDTs in commu-
nity pharmacies which is pertinent to mention. There 
is a need to regulate the price of RDT in the commu-
nity pharmacies so as to avoid outrageous mark up. For 
instance, Poyer et  al. [43] showed that median RDT 
prices were higher in pharmacies compared to other 
health care centers. Uncontrolled RDT price in com-
munity pharmacies could contribute substantial cost to 
the treatment of malaria with the end result felt mostly 
by those in the lower socio-economic strata. Such will 
cause treatment of malaria to be catastrophic especially 
considering that about 99 million Nigerians (58%) live 
with less than US$1.25 per day [44]. Additionally, RDT 
accuracy in malaria case management is highly user-
dependent despite their apparent simplicity [45]. Many of 
the errors with malaria RDT kit are related to the post-
analytical phase, i.e. wrong reading of the test and control 
lines and incorrect interpretation of the results [45, 46]. 
Therefore, quality assessment on the use of malaria RDT 
test in pharmacies should be promoted through moni-
toring. For instance, Pharmacist Council of Nigeria (the 
Table 3 Cost and benefit data
Variable Average [min–max] (US$) Distribution Source
Staff salary/month
 Locum (n = 36) 67.56 [60.30–100.50] Interview
 Full time pharmacist (n = 22) 389.45 [251.26–452.26] Interview
 Superintendent pharmacist (n = 27) 402.01 [351.76–502.51] Interview
Staff cost (15 min) 0.41 [0.18–0.52] Triangular –
RDT kit (n = 12) 0.15 [0.13–0.17] Triangular Market survey
WTP for RDT 1.23 [0.0–5.03] Triangular Survey
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body in-charge of regulating pharmacy practice in Nige-
ria) or Association of Community Pharmacists of Nige-
ria (ACPN) could incorporate monitoring of RDT use in 
pharmacy premises as part of their responsibilities.
A drawback to the findings is the issue of generalizing 
the result which should be considered while interpret-
ing the result. Notwithstanding, effort was made to select 
a city with a fair representation of community pharmacy 
practice in Nigeria especially since all cadres of commu-
nity pharmacies operate in Enugu. Secondly, community 
pharmacies in Nigeria tend to cluster around the cities and 
this means that people living in rural areas are potentially 
excluded from the study. This is evident as about 78% of 
the study participants had tertiary education which con-
trast markedly with the national average of 7.1% [47]. Also, 
the WTP value obtained in this study should be consid-
ered in view of bias associated with payment scale/card 
elicitation format. Participants could have been influenced 
by the range of values chosen for the payment scale ques-
tion design instead of their true maximum WTP values. 
However, in order to mitigate this bias, several payment 
scales with different ranges were used. Since only patients 
with suspected cases of malaria infection were included, 
their possible illness could have made them more likely to 
pay for RDT even under circumstances where they would 
have behaved otherwise. Lastly, the small sample size of 
RDT rejecters could have induced a systematic bias as 
logistic regression could overestimate odd ratios in studies 
with small to moderate sample size [48].
Conclusion
Malaria testing using RDT before recommending malaria 
treatment for those that tested positive is a cost-benefi-
cial practice for community pharmacy practitioners with 
a return on investment of 6.7 times. This finding could 
serve as an advocacy tool to increase community phar-
macy practitioners’ interest and uptake of test-based 
malaria treatment. Consequently, increase in uptake of 
test-based malaria treatment would help to reduce over-
diagnosis of malaria, over-prescription of anti-malarial 
drugs, and invariably the cost of treatment especially if 
the testing is done appropriately and community phar-
macists and patients adhere to the results.
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